Functional 3D-bioprinted hPSC-derived cardiac patches enhance cardiac repair following ischemia-reperfusion injury
Frontiers in Cardiovascular Medicine · 18.11.2026 · 13
DOI: 10.3389/fcvm.2026.1868394 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Cardiovascular Medicine, online erschienen am 18.11.2026. Verfasst von A. N. K. V. Sravani und 1 weiteren Autor:innen. Die Arbeit nennt 109 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Myocardial ischemia-reperfusion (I/R) injury is a leading cause of heart failure, as reperfusion therapy restores blood flow but does not replace necrotic myocardium or prevent further remodelling. Myocardial regeneration relies heavily on cardiomyocytes derived from human pluripotent stem cells (hPSC-CMs). Multiple studies have demonstrated that custom-engineered cardiac tissues or organoids can show a resemblance to functional recovery after an infarction. Several reviews have analysed the overall developments in scaffold-based tissue engineering, cardiac organoids, and stem cell differentiation and associated technologies. But most of them have failed to consider how these technologies function in the oxidative, inflammatory, and hypoxic environment that characterizes the I/R injury. According to recent studies, 3D bio-printed cardiac patches improve graft retention, vascularisation, and electrical coupling. However, the mechanisms by which design parameters (bioink composition, oxygen diffusion, electromechanical alignment, etc.) confer resistance to reperfusion stress remain unclear. Despite these promising developments, significant translational obstructions remain unanswered, such as Immature hPSC-derived cardiomyocytes, insufficient vascularization, restricted long-term engraftment, immunological compatibility, and large-scale manufacturing, all of which limit the therapeutic applicability of modified cardiac patches. Thus, successful cardiac regeneration will require not only enhanced biofabrication technology but also pathophysiology-guided design methodologies capable of overcoming the adverse post-ischemic environment. To fill this gap, this review focuses on how the molecular mechanisms of myocardial ischemia-reperfusion injury, such as oxidative stress, inflammation, mitochondrial dysfunction, calcium overload, hypoxia, and adverse remodelling, can be directly translated into the logical design of bioactive cardiac patches that can overcome these pathological barriers, in contrast to earlier reviews that provide a general overview of cardiac tissue engineering. Consequently, we hope this associating study proposes a disease-specific framework that would allow the biofabrication of clinically relevant cardiac patches that incorporate cardioprotective processes, such as metabolic reprogramming, mitochondrial preservation, and paracrine signaling. This review emphasizes a link between pathophysiology-informed bioprinting for functional myocardial healing and generic cardiac architecture.
Zitieren
APA
Sravani, A. N. K. V., & Thomas, J. (2026). Functional 3D-bioprinted hPSC-derived cardiac patches enhance cardiac repair following ischemia-reperfusion injury. Frontiers in Cardiovascular Medicine, 13. https://doi.org/10.3389/fcvm.2026.1868394
Vancouver
Sravani ANKV, Thomas J. Functional 3D-bioprinted hPSC-derived cardiac patches enhance cardiac repair following ischemia-reperfusion injury. Frontiers in Cardiovascular Medicine. 2026;13. doi:10.3389/fcvm.2026.1868394
BibTeX
@article{Sravani2026,
author = {Sravani, A. N. K. V. and Thomas, John},
title = {Functional 3D-bioprinted hPSC-derived cardiac patches enhance cardiac repair following ischemia-reperfusion injury},
journal = {Frontiers in Cardiovascular Medicine},
year = {2026},
volume = {13},
doi = {10.3389/fcvm.2026.1868394}
}
EUVIMED